NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2010

Primary Completion Date

February 16, 2016

Study Completion Date

February 16, 2017

Conditions

Malignant Melanoma

Interventions

DRUG

IMCgp100

For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.

Trial Locations (9)

10065

Memorial Slone Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

90025

The Angeles Clinic, Los Angeles

06520-8028

Yale Cancer Center, New Haven

Unknown

Queen Elizabeth Hospital, Birmingham

Addenbrooke's Hospital, Cambridge

The Beatson Institute, Glasgow

St James Hospital, Leeds

NIHR Biomedical Research Centre, Oxford